Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
US10934336B2 · kind B2 · utility
6Cited by
5References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2018 |
| Grant date | Mar 2, 2021 |
| Priority date | — |
| Expiry date | Apr 12, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.